Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.
Thermo Fisher: A Dividend Investor's Lab Partner For Growth And Stability
Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.
3 Nanotechnology Stocks With Microscopic Risk
Given the expanding size of the nanotechnology industry, buying nanotechnology stocks with a very low-risk profile is possible. Electronics is one of the most important sectors that applies nanotechnology.
Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
Thermo Fisher (TMO) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Thermo Fisher Q2 Earnings Beat Estimates, Guidance Lifted
Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.37 per share, beating the Zacks Consensus Estimate of $5.13 per share. This compares to earnings of $5.15 per share a year ago.
Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement
Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Stock Of The Day: How To Predict Thermo Fisher Scientific Trend Reversals
Stocks tend to sell off after they reach resistance. They also tend to rally off of support.
